Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Barclays PLC Director's Dealing 2021

Mar 22, 2021

5250_rns_2021-03-22_ff371cd9-910c-4532-8cd6-880f4cdbf80e.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

FORM 38.5(B) - OSMOTICA PHARMACEUTICALS PLC

FORM 38.5(b)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

1. KEY INFORMATION

Name of exempt principal trader: BARCLAYS CAPITAL INC
Company dealt in OSMOTICA PHARMACEUTICALS PLC
Class of relevant security to which the US$0.01 ordinary shares
dealings being disclosed relate
Date of dealing 19 March 2021

2. INTERESTS AND SHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

Class of relevant security: ORD
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
320 0.00% 0 0.00%
(2) Derivatives (other than options):
0 0.00% 0 0.00%
(3) Options and agreements to
purchase/sell: 0 0.00% 0 0.00%
(4)
TOTAL: 320 0.00% 0 0.00%

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap28

3. DEALINGS (Note 3)

a. Purchases and sales

Purchase/sale Number of Price per unit
securities
Purchase 14 3.8700 USD
Purchase 100 3.7850 USD
Purchase 100 3.8250 USD
Purchase 100 3.8150 USD
Purchase 100 3.8200 USD
Purchase 158 3.8415 USD
Purchase 200 3.8175 USD
Purchase 500 3.8080 USD
Purchase 4,697 3.8124 USD
Purchase 5,292 3.7300 USD
Sale 5,306 3.8700 USD
Sale 5,955 3.8129 USD

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 5)
Number of relevant securities

(Note 6)
Price per unit

(Note 4)

c. Options transactions in respect of existing relevant securities

i. Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 4)

ii. Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 4)

d. Other dealings (including transactions in respect of new securities) (Note 3)

Nature of transaction

(Note 7)
Details Price per unit

(if applicable) (Note 4)

Ap29

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 38.5(b) attached? NO
Date of disclosure: 22 Mar 2021
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213
Name of offeree/offeror with which connected
Nature of connection

View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005359/en/

BARCLAYS PLC